Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (28)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2023

  1. HIV medical care interruption among people living with HIV in Spain, 2004-2020

    AIDS, Vol. 37, Núm. 8, pp. 1277-1284

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271

  2. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 3, pp. 738-742

2020

  1. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

    EBioMedicine, Vol. 55

  2. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: Comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen

    HIV Medicine, Vol. 15, Núm. 9, pp. 547-556

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  3. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2010

  1. Misindentification of Mycobacterium kumamotonense as M. tuberculosis

    Emerging Infectious Diseases

2008

  1. Immunological predictors of CD4 + T cell decline in antiretroviral treatment interruptions

    BMC Infectious Diseases, Vol. 8

  2. Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption

    Journal of Acquired Immune Deficiency Syndromes, Vol. 48, Núm. 4, pp. 455-459

2004

  1. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

    Journal of Antimicrobial Chemotherapy, Vol. 53, Núm. 3, pp. 540-543

  2. Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects

    Vaccine, Vol. 22, Núm. 23-24, pp. 2966-2973